Dubois RN, Abramson SB, Crofford L. Cycloxygenase in biology and disease. FASEB J. 1998;12:1063-1073.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.

DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci. 1988;85:1412-1416.

Kujubu DA, Fletcher BS, Varnum BC. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/ciclooxygenase homologue. J Biol Chem. 1991;266:12866-12872.

Xie W, Chipman JG, Robertson DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci. 1991;88:2692-2696.

Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol. 1997;24:15-19.

Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.

Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol. 2000;22:291-298.

Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxigenase-2. N Engl J Med. 2001;345:433-442.

Carvalho WA, Lemonica L. Mecanismos Celulares e Moleculares da Dor Inflamatória: Modulação Periférica e Avanços Terapêuticos. Temas de Anestesiologia: Curso de Graduação em Medicina. 2000:265-280.

Chandrasekharan NV, Dai H, Roos KL. COX-3, a cyclooxygensase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci. 2002;99:13926-13931.

Janeway CA, Travers P, Walport M. Immunobiology: The Immune System in Health and Disease. 2001.

Morrow JD, Roberts LJ. Lipid-Derived Autacoids: Eicosanoids and Platelet-Activating Factor. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 2001:669-685.

Carvalho WA. Analgésicos, Antipiréticos e Antiinflamatórios. Farmacologia. 2002:431-455.

Samuelsson B, Granstrom E, Green K. Prostaglandins. Ann Rev Biochem. 1975;44:669-694.

Samuelsson B. The leukotrienens: a new group of biologically active compounds including SRS-A. Trends Pharmacol Sci. 1980;1:227-230.

Carvalho WA. Mecanismos de ação das drogas anti- inflamatórias não-esteróides: I. Ações farmacológicas das prostaglandinas e leucotrienos. F Med. 1990;100:37-44.

Carvalho WA. Mecanismos de ação de drogas antiinflamatórias não-esteróides: II. Ações analgésicas, antiinflamatórias e antipiréticas. F Med. 1990;100:111-122.

Raz A, Wyche A, Needleman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phases. Proc Natl Acad Sci. 1989;86:1657-1661.

Fu JY, Masferrer JL, Seibert K. The induction and suppression of prostaglandin H2 synthase (cyclooxigenase) in human monocytes. J Biol Chem. 1990;265:16737-16740.

Mitchell JA, Akarasereenont P, Thiemermann C. Selectivity of nonsteroid anti-inflammatory drugs as inhibitors of constitutive and inducible ciclooxygenase. Proc Natl Acad Sci. 1993;90:11693-11697.

Meade EA, Smith WL, Dewitt DL. Differential inhibition of spinal nociceptive processing. Pain. 1993:9-43.

Vane JR, Bottingg RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res. 1995:1-10.

Jouzeau Y, Terlain B, Abid A. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs. 1997;53:563-582.

Morisset S, Patry C, Lora, M. Regulation of cyclooxygense-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol. 1998;25:1146-1153.

Hinz B, Brune K. Cyclooxygenase-2 10 years later. J. Pharmacol. Exp Ther. 2002;300:367-375.

Kurumbail RG, Stevens AM, Gierse JK. Structural basis for selective inhibition of cyclooxigenase-2 by anti-inflammatory agents. Nature. 1996;384:644-648.

Cryer B, Dubois A. The advent of higly selective inhibitors of cyclooxigenase: A review. Prostaglandins. 1998;56:341-361.

Needleman P. In search of a better NSAID. Proceedings. 1994:6-10.

Devchand PR, Keller H, Peters JH. The PPARalpha- leukotriene B4 pathway to inflammatory control. Nature. 1996;384:39-43.

Hla T, Bishop-Bailey D, Liu CH. Cyclooxygenase-1 and -2 isoenzymes. Int J Bioch Cell Biol. 1999;31:551-557.

Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors and clinical potential distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-229.

Graziano MP, Gilman AG. Guanine nucleotide-binding regulatory protein: mediators of transmembrane signaling. Trends Pharmacol Sci. 1987;8:478-481.

Colville-Nash PR, Qureshi SS, Willis D. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol. 1998;161:978-984.

Gilroy DW, Tomlinson A, Willoughby DA. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res. 1998;47:79-85.

Gilroy DW, Colville-Nash PR, Willis D. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 1999;5:698-701.

Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.

Ricote M, Huang J, Fajas L. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998;95:7614-7619.

Ricote M, Li AC, Willson TM. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.

Willoughby DA, Moore AR, Colville-Nash PR. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 2000;355:646-648.

Carvalho WA, Lemonica L. Mecanismos Centrais de Transmissão e de Modulação da Dor: Atualização Terapêutica. Temas de Anestesiologia: para o Curso de Graduação em Medicina. 2000:281-296.

Ferreira SH, Vane JR. Mode of Action of Anti-Inflammatory Agents which are Prostaglandin Synthetase Inhibitory. Anti-Inflammatory Drugs. 1979:348-398.

Moncada S, Ferreira SH, Vane JR. Pain and Inflammatory Mediators. Hand Books of Experimental Inflammation. 1978:588-616.

Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30:293-331.

Piper P, Vane J. The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci. 1971;180:383-385.

Fischer JW, Gross DM. Effects of Prostaglandins on Erythropoiesis. Prostaglandins in Haematology. 1977:159-185.

Cohn SM, Schloemann S, Tessner T. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. J Clin Invest. 1997;99:1367-1379.

Yamagata K, Andreasson KI, Kaufmann WE. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and gluccorticoids. Neuron. 1993;11:371-386.

Breder C, Saper CB. Expression of inducible cycloxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolyssaccharide. Brain Res. 1996;713:64-69.

Kaufmann WE, Worley PF, Pegg J. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci. 1996;93:2317-2321.

Fiebich BL, Hull M, Lieb K. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem. 1997;68:704-709.

Panara MR, Renda G, Sciulli MG. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. J Pharmacol Exp Ther. 1999;290:276-280.

Picot D, Loll PJ, Garavito RM. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase 1. Nature. 1994;367:243-249.

Hull M, Lieb K, Fiebich BL. Anti-inflammatory drugs: a hope for Alzheimer's disease?. Expert Opin Investig Drugs. 2000;9:671-683.

Hawkeu CJ. COX-2 Inhibitors. Nature. 1999;353:307-314.

Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for coloretal cancer prevention. J Clin Invest. 1997;100:1325-1329.

Baron JA, Cole BF, Sandler RS. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.

Sandler RS, Halabi S, Baron JA. A randomized trial of aspirin to prevent corectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.

Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene. 2001;20:4450-4456.

Steinbach G, Lynch PM, Phillips RKS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Eng J Med. 2000;342:1946-1952.

Kundu N, Fulton AM. Selective cyclooxygenase COX-1 or COX-2 inhibits control metastatic disease in a murine model of breast cancer. Cancer Res. 2002;62:2343-2346.

Kaur BS, Khamnehei N, Iravani M. Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology. 2002;123:60-67.

Singh-Ranger G, Mokbel K. Current concepts in cyclooxygenase inhibition in breast cancer. J Clin Pharm Ther. 2002;27:321-327.

Wu GD. A nuclear receptor to prevent colon cancer. N Engl J Med. 2000;342:651-653.

He TC, Chan TA, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335-345.

Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli min mouse model with aspirin. Gastroenterology. 1998;114:873-877.

Lynch HT, Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919-932.

Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer. 2003;103:84-90.

Eibl G, Reber HA, Wente MN. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas. 2003;26:33-41.

Subongkot S, Frame D, Leslie W. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy. 2003;23:9-28.

Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954-959.

Mukherjee D, Nissen SE, Topol EJ. COX-2 inhibitors and cardiovascular risk: we defend our data and suggest caution. Cleve Clin J Med. 2001;68:963-964.

Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specific inhibitors. Am J Med. 2001;110(^sSuppl):33S-42S.

Grob M, Scheidegger P, Wuthrich B. Allergic skin reaction to celecoxib. Dermatology. 2000;201:383.

Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides?: Revisiting the meaning of 'sulfa' allergy. Drug Saf. 2001;24:239-247.

Ahmad SR, Kortepeter C, Brinker A. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25:537-544.

Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy. 2002;22:637-640.

Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet. 2001;357:1946-1947.

Schneider F, Meziani F, Chartier C. Fatal allergic vasculitis associated with celecoxib. Lancet. 2002;359:852-853.

FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542-544.

MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.